CALGARY, Alberta, Sept. 23, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the Late Breaking Science submission, regarding the primary results of the BETonMACE trial, has been accepted by the American Heart Association (“AHA”) for presentation during Scientific Sessions 2019 held in Philadelphia, Pennsylvania. The trial results […]
Other News
InspireMD, Inc. Announces Pricing of $5 Million Underwritten Public Offering
TEL AVIV, Israel, Sept. 19, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 2,777,777 units at a price to the public of […]
LimFlow Receives FDA Approval for U.S. Pivotal Study of Minimally-Invasive Technology Designed to Prevent Amputations in Chronic Limb-Threatening Ischemia Patients
PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption for the PROMISE II pivotal study of the LimFlow Percutaneous Deep […]
Aspect Imaging Announces Exclusive Agreement with Scintica Instrumentation for Distribution of its Pre-Clinical Imaging Systems
NASHVILLE, Tenn., Sept. 18, 2019 /PRNewswire/ — Aspect Imaging, Ltd., a global leader in the design and development of state-of-the-art, high resolution MR imaging solutions for pre-clinical and medical applications, has signed an exclusive agreement with Scintica Instrumentation Inc. for the distribution of its M-Series™ MRI systems. With more than 100 MRI installations […]
Sequana Medical Appoints Leading Experts as Heart Failure Scientific Advisors
Dr. Butler, Dr. Costanzo, Dr. Tang and Dr. Testani to advise on alfapump® DSR development GHENT, Belgium, Sept. 19, 2019 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), innovators in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the […]
JenaValve Technology Strengthens Senior Leadership Team in Clinical Affairs and Operations
IRVINE, Calif.–(BUSINESS WIRE)–JenaValve Technology, Inc., a developer of a novel transcatheter aortic valve replacement (TAVR) system for the treatment of aortic valve disease, today announced the appointment of two veteran medical device executives Vinny Podichetty, MD, MS as Vice President, Clinical Affairs, and Jeff Thiel as Vice President, Operations, effective […]
Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors
Post-hoc analysis of the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin based on the number of cardiovascular risk factor goals achieved.1 Findings from the post-hoc analysis were presented at the 55th Annual Meeting of the European Association for the Study […]
Novant Health selects prescriptive analytics leader Jvion as inaugural partner for new Institute of Innovation & Artificial Intelligence
Initial program aims to reduce congestive heart failure readmissions with potential savings of about $1M ATLANTA, Sept. 18, 2019 (GLOBE NEWSWIRE) — Jvion, a leader in AI-enabled prescriptive analytics for preventable harm, today announced a partnership with Novant Health as part of the newly launched Novant Health Institute of Innovation & Artificial Intelligence. Working […]
Study Finds Immunosuppressive Therapy Increases Risk of Cardiovascular Incident
SAN DIEGO, Sept. 17, 2019 /PRNewswire/ — Abcentra, a clinical-stage bio-pharmaceutical company that addresses unmet needs in inflammation, today announced its contribution to a 2019 study published in the American Heart Association Journals. The study found that, in those with high-cholesterol and major histocompatibility complex class II (MHCII) cells, treating atherosclerosis with immunotherapy […]
Abbott Announces European Approval of Two Life-saving Heart Devices for Babies and Children
– World’s smallest pediatric treatments pioneered by Abbott address critical needs for the most vulnerable patients: babies and children born with common congenital heart defects – Includes pediatric mechanical heart valve and first minimally invasive device to treat premature babies and newborns born with an opening in their heart […]



